Montag & Caldwell LLC Sells 1,285 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Montag & Caldwell LLC lowered its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 8.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 14,787 shares of the medical research company’s stock after selling 1,285 shares during the period. Thermo Fisher Scientific makes up about 1.6% of Montag & Caldwell LLC’s holdings, making the stock its 24th biggest position. Montag & Caldwell LLC’s holdings in Thermo Fisher Scientific were worth $7,693,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Jump Financial LLC boosted its stake in Thermo Fisher Scientific by 1,545.2% in the 4th quarter. Jump Financial LLC now owns 49,011 shares of the medical research company’s stock worth $25,497,000 after purchasing an additional 46,032 shares during the period. Anchor Investment Management LLC grew its stake in Thermo Fisher Scientific by 0.9% during the fourth quarter. Anchor Investment Management LLC now owns 11,465 shares of the medical research company’s stock valued at $5,965,000 after acquiring an additional 99 shares in the last quarter. Kane Investment Management Inc. purchased a new stake in Thermo Fisher Scientific in the 4th quarter worth approximately $747,000. Guggenheim Capital LLC boosted its holdings in Thermo Fisher Scientific by 6.1% in the 4th quarter. Guggenheim Capital LLC now owns 40,621 shares of the medical research company’s stock valued at $21,132,000 after purchasing an additional 2,328 shares during the period. Finally, Rossby Financial LCC bought a new position in shares of Thermo Fisher Scientific in the fourth quarter worth $920,000. 89.23% of the stock is owned by institutional investors.

Insider Transactions at Thermo Fisher Scientific

In related news, EVP Gianluca Pettiti sold 300 shares of the firm’s stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total transaction of $175,677.00. Following the sale, the executive vice president now directly owns 16,363 shares of the company’s stock, valued at $9,582,009.17. This trade represents a 1.80 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $516.67, for a total value of $5,166,700.00. Following the completion of the transaction, the chief executive officer now directly owns 115,174 shares of the company’s stock, valued at $59,506,950.58. The trade was a 7.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 23,900 shares of company stock worth $13,106,062. Company insiders own 0.34% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the company. UBS Group upped their target price on Thermo Fisher Scientific from $700.00 to $715.00 and gave the stock a “buy” rating in a research note on Friday, January 31st. Raymond James reissued an “outperform” rating and set a $667.00 price target (up from $650.00) on shares of Thermo Fisher Scientific in a research note on Monday, February 3rd. Barclays cut their price target on shares of Thermo Fisher Scientific from $620.00 to $475.00 and set an “equal weight” rating for the company in a research report on Thursday, April 10th. Sanford C. Bernstein upgraded Thermo Fisher Scientific from a “market perform” rating to an “outperform” rating and set a $630.00 target price for the company in a report on Friday, January 10th. Finally, Morgan Stanley boosted their price objective on Thermo Fisher Scientific from $647.00 to $678.00 and gave the company an “overweight” rating in a research report on Friday, January 31st. Four equities research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $647.43.

Thermo Fisher Scientific Stock Up 2.4 %

NYSE:TMO opened at $448.60 on Tuesday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66. The stock has a market capitalization of $169.24 billion, a P/E ratio of 27.14, a P/E/G ratio of 2.99 and a beta of 0.86. The company’s 50-day simple moving average is $507.90 and its 200-day simple moving average is $537.62. Thermo Fisher Scientific Inc. has a fifty-two week low of $409.85 and a fifty-two week high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Thursday, January 30th. The medical research company reported $6.10 EPS for the quarter, beating the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. On average, equities analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, April 15th. Shareholders of record on Friday, March 14th will be paid a dividend of $0.43 per share. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. The ex-dividend date of this dividend is Friday, March 14th. This represents a $1.72 dividend on an annualized basis and a yield of 0.38%. Thermo Fisher Scientific’s dividend payout ratio is presently 10.41%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.